nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—type 2 diabetes mellitus—polycystic ovary syndrome	0.797	1	CtDrD
Irbesartan—Seasonal allergy—Metformin—polycystic ovary syndrome	0.00574	0.0881	CcSEcCtD
Irbesartan—Rhinitis seasonal—Metformin—polycystic ovary syndrome	0.00551	0.0846	CcSEcCtD
Irbesartan—Distention—Metformin—polycystic ovary syndrome	0.0051	0.0784	CcSEcCtD
Irbesartan—Abnormal faeces—Metformin—polycystic ovary syndrome	0.00421	0.0646	CcSEcCtD
Irbesartan—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.00229	0.0351	CcSEcCtD
Irbesartan—CYP1A2—urine—polycystic ovary syndrome	0.0021	0.0499	CbGeAlD
Irbesartan—CYP2C9—urine—polycystic ovary syndrome	0.00199	0.0473	CbGeAlD
Irbesartan—Respiratory distress—Metformin—polycystic ovary syndrome	0.00189	0.0291	CcSEcCtD
Irbesartan—JUN—embryo—polycystic ovary syndrome	0.00177	0.0422	CbGeAlD
Irbesartan—Heartburn—Metformin—polycystic ovary syndrome	0.00175	0.0268	CcSEcCtD
Irbesartan—UGT1A3—endocrine gland—polycystic ovary syndrome	0.00161	0.0382	CbGeAlD
Irbesartan—EDNRA—adrenal cortex—polycystic ovary syndrome	0.00159	0.0379	CbGeAlD
Irbesartan—CYP3A4—urine—polycystic ovary syndrome	0.00152	0.0361	CbGeAlD
Irbesartan—CYP2D6—urine—polycystic ovary syndrome	0.00149	0.0355	CbGeAlD
Irbesartan—JUN—adrenal cortex—polycystic ovary syndrome	0.00145	0.0346	CbGeAlD
Irbesartan—EDNRA—endometrium—polycystic ovary syndrome	0.00142	0.0338	CbGeAlD
Irbesartan—EDNRA—uterus—polycystic ovary syndrome	0.00131	0.0312	CbGeAlD
Irbesartan—JUN—endometrium—polycystic ovary syndrome	0.0013	0.0309	CbGeAlD
Irbesartan—EDNRA—pituitary gland—polycystic ovary syndrome	0.00129	0.0306	CbGeAlD
Irbesartan—EDNRA—adipose tissue—polycystic ovary syndrome	0.00128	0.0305	CbGeAlD
Irbesartan—JUN—uterus—polycystic ovary syndrome	0.0012	0.0284	CbGeAlD
Irbesartan—JUN—pituitary gland—polycystic ovary syndrome	0.00117	0.0279	CbGeAlD
Irbesartan—JUN—adipose tissue—polycystic ovary syndrome	0.00117	0.0278	CbGeAlD
Irbesartan—EDNRA—adrenal gland—polycystic ovary syndrome	0.00115	0.0273	CbGeAlD
Irbesartan—AGTR1—adrenal cortex—polycystic ovary syndrome	0.00109	0.026	CbGeAlD
Irbesartan—Lightheadedness—Metformin—polycystic ovary syndrome	0.00108	0.0165	CcSEcCtD
Irbesartan—EDNRA—female gonad—polycystic ovary syndrome	0.00107	0.0255	CbGeAlD
Irbesartan—EDNRA—vagina—polycystic ovary syndrome	0.00107	0.0253	CbGeAlD
Irbesartan—JUN—adrenal gland—polycystic ovary syndrome	0.00105	0.025	CbGeAlD
Irbesartan—Ear pain—Metformin—polycystic ovary syndrome	0.00102	0.0157	CcSEcCtD
Irbesartan—JUN—female gonad—polycystic ovary syndrome	0.000978	0.0233	CbGeAlD
Irbesartan—JUN—vagina—polycystic ovary syndrome	0.000972	0.0231	CbGeAlD
Irbesartan—Injury—Metformin—polycystic ovary syndrome	0.00095	0.0146	CcSEcCtD
Irbesartan—Renal impairment—Metformin—polycystic ovary syndrome	0.000917	0.0141	CcSEcCtD
Irbesartan—JUN—endocrine gland—polycystic ovary syndrome	0.00091	0.0216	CbGeAlD
Irbesartan—AGTR1—pituitary gland—polycystic ovary syndrome	0.000884	0.021	CbGeAlD
Irbesartan—AGTR1—adipose tissue—polycystic ovary syndrome	0.000881	0.0209	CbGeAlD
Irbesartan—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000806	0.0124	CcSEcCtD
Irbesartan—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000797	0.0122	CcSEcCtD
Irbesartan—AGTR1—adrenal gland—polycystic ovary syndrome	0.00079	0.0188	CbGeAlD
Irbesartan—Breast disorder—Metformin—polycystic ovary syndrome	0.000789	0.0121	CcSEcCtD
Irbesartan—Cramp muscle—Metformin—polycystic ovary syndrome	0.000786	0.0121	CcSEcCtD
Irbesartan—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000781	0.012	CcSEcCtD
Irbesartan—Abdominal distension—Metformin—polycystic ovary syndrome	0.00076	0.0117	CcSEcCtD
Irbesartan—Influenza—Metformin—polycystic ovary syndrome	0.000755	0.0116	CcSEcCtD
Irbesartan—Pancreatitis—Metformin—polycystic ovary syndrome	0.00074	0.0114	CcSEcCtD
Irbesartan—Angina pectoris—Metformin—polycystic ovary syndrome	0.000735	0.0113	CcSEcCtD
Irbesartan—AGTR1—vagina—polycystic ovary syndrome	0.000732	0.0174	CbGeAlD
Irbesartan—Neutropenia—Metformin—polycystic ovary syndrome	0.000706	0.0108	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000701	0.0108	CcSEcCtD
Irbesartan—AGTR1—endocrine gland—polycystic ovary syndrome	0.000685	0.0163	CbGeAlD
Irbesartan—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000636	0.00977	CcSEcCtD
Irbesartan—Bradycardia—Metformin—polycystic ovary syndrome	0.000615	0.00944	CcSEcCtD
Irbesartan—Rhinitis—Metformin—polycystic ovary syndrome	0.000606	0.0093	CcSEcCtD
Irbesartan—Hepatitis—Metformin—polycystic ovary syndrome	0.000604	0.00927	CcSEcCtD
Irbesartan—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000601	0.00923	CcSEcCtD
Irbesartan—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000595	0.00914	CcSEcCtD
Irbesartan—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000594	0.00911	CcSEcCtD
Irbesartan—Flushing—Metformin—polycystic ovary syndrome	0.000561	0.00861	CcSEcCtD
Irbesartan—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000561	0.00861	CcSEcCtD
Irbesartan—Angiopathy—Metformin—polycystic ovary syndrome	0.000548	0.00841	CcSEcCtD
Irbesartan—Immune system disorder—Metformin—polycystic ovary syndrome	0.000546	0.00838	CcSEcCtD
Irbesartan—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000544	0.00836	CcSEcCtD
Irbesartan—Chills—Metformin—polycystic ovary syndrome	0.000542	0.00832	CcSEcCtD
Irbesartan—CYP2C8—endometrium—polycystic ovary syndrome	0.00053	0.0126	CbGeAlD
Irbesartan—Erythema—Metformin—polycystic ovary syndrome	0.000526	0.00807	CcSEcCtD
Irbesartan—Malnutrition—Metformin—polycystic ovary syndrome	0.000526	0.00807	CcSEcCtD
Irbesartan—Flatulence—Metformin—polycystic ovary syndrome	0.000518	0.00796	CcSEcCtD
Irbesartan—Dysgeusia—Metformin—polycystic ovary syndrome	0.000515	0.00791	CcSEcCtD
Irbesartan—Muscle spasms—Metformin—polycystic ovary syndrome	0.000506	0.00776	CcSEcCtD
Irbesartan—Vision blurred—Metformin—polycystic ovary syndrome	0.000496	0.00761	CcSEcCtD
Irbesartan—Tremor—Metformin—polycystic ovary syndrome	0.000493	0.00756	CcSEcCtD
Irbesartan—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000488	0.00749	CcSEcCtD
Irbesartan—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00048	0.0114	CbGeAlD
Irbesartan—Malaise—Metformin—polycystic ovary syndrome	0.000474	0.00728	CcSEcCtD
Irbesartan—Syncope—Metformin—polycystic ovary syndrome	0.000472	0.00724	CcSEcCtD
Irbesartan—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000462	0.0071	CcSEcCtD
Irbesartan—Hypertension—Metformin—polycystic ovary syndrome	0.000454	0.00697	CcSEcCtD
Irbesartan—Myalgia—Metformin—polycystic ovary syndrome	0.000448	0.00687	CcSEcCtD
Irbesartan—Chest pain—Metformin—polycystic ovary syndrome	0.000448	0.00687	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000445	0.00683	CcSEcCtD
Irbesartan—Discomfort—Metformin—polycystic ovary syndrome	0.000442	0.00679	CcSEcCtD
Irbesartan—PTGS1—endometrium—polycystic ovary syndrome	0.00043	0.0102	CbGeAlD
Irbesartan—Oedema—Metformin—polycystic ovary syndrome	0.000429	0.00659	CcSEcCtD
Irbesartan—Infection—Metformin—polycystic ovary syndrome	0.000426	0.00655	CcSEcCtD
Irbesartan—Shock—Metformin—polycystic ovary syndrome	0.000422	0.00648	CcSEcCtD
Irbesartan—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000421	0.00646	CcSEcCtD
Irbesartan—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00042	0.00645	CcSEcCtD
Irbesartan—Skin disorder—Metformin—polycystic ovary syndrome	0.000417	0.0064	CcSEcCtD
Irbesartan—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000415	0.00637	CcSEcCtD
Irbesartan—Anorexia—Metformin—polycystic ovary syndrome	0.000409	0.00628	CcSEcCtD
Irbesartan—Hypotension—Metformin—polycystic ovary syndrome	0.000401	0.00616	CcSEcCtD
Irbesartan—CYP2C8—vagina—polycystic ovary syndrome	0.000397	0.00944	CbGeAlD
Irbesartan—PTGS1—uterus—polycystic ovary syndrome	0.000396	0.00942	CbGeAlD
Irbesartan—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000391	0.006	CcSEcCtD
Irbesartan—PTGS1—pituitary gland—polycystic ovary syndrome	0.000389	0.00925	CbGeAlD
Irbesartan—PTGS1—adipose tissue—polycystic ovary syndrome	0.000387	0.00921	CbGeAlD
Irbesartan—Paraesthesia—Metformin—polycystic ovary syndrome	0.000385	0.00592	CcSEcCtD
Irbesartan—Dyspnoea—Metformin—polycystic ovary syndrome	0.000383	0.00587	CcSEcCtD
Irbesartan—Somnolence—Metformin—polycystic ovary syndrome	0.000382	0.00586	CcSEcCtD
Irbesartan—Dyspepsia—Metformin—polycystic ovary syndrome	0.000378	0.0058	CcSEcCtD
Irbesartan—Decreased appetite—Metformin—polycystic ovary syndrome	0.000373	0.00573	CcSEcCtD
Irbesartan—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000371	0.00883	CbGeAlD
Irbesartan—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00037	0.00569	CcSEcCtD
Irbesartan—Fatigue—Metformin—polycystic ovary syndrome	0.00037	0.00568	CcSEcCtD
Irbesartan—Constipation—Metformin—polycystic ovary syndrome	0.000367	0.00563	CcSEcCtD
Irbesartan—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000354	0.00543	CcSEcCtD
Irbesartan—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000351	0.00539	CcSEcCtD
Irbesartan—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000348	0.00827	CbGeAlD
Irbesartan—PTGS1—adrenal gland—polycystic ovary syndrome	0.000347	0.00826	CbGeAlD
Irbesartan—Urticaria—Metformin—polycystic ovary syndrome	0.000341	0.00523	CcSEcCtD
Irbesartan—Abdominal pain—Metformin—polycystic ovary syndrome	0.000339	0.00521	CcSEcCtD
Irbesartan—CYP2C9—endocrine gland—polycystic ovary syndrome	0.00033	0.00785	CbGeAlD
Irbesartan—PTGS1—female gonad—polycystic ovary syndrome	0.000324	0.0077	CbGeAlD
Irbesartan—PTGS1—vagina—polycystic ovary syndrome	0.000322	0.00766	CbGeAlD
Irbesartan—Asthenia—Metformin—polycystic ovary syndrome	0.000308	0.00473	CcSEcCtD
Irbesartan—Pruritus—Metformin—polycystic ovary syndrome	0.000304	0.00466	CcSEcCtD
Irbesartan—PTGS1—endocrine gland—polycystic ovary syndrome	0.000301	0.00716	CbGeAlD
Irbesartan—Diarrhoea—Metformin—polycystic ovary syndrome	0.000294	0.00451	CcSEcCtD
Irbesartan—Dizziness—Metformin—polycystic ovary syndrome	0.000284	0.00436	CcSEcCtD
Irbesartan—Vomiting—Metformin—polycystic ovary syndrome	0.000273	0.00419	CcSEcCtD
Irbesartan—Rash—Metformin—polycystic ovary syndrome	0.000271	0.00415	CcSEcCtD
Irbesartan—Dermatitis—Metformin—polycystic ovary syndrome	0.00027	0.00415	CcSEcCtD
Irbesartan—Headache—Metformin—polycystic ovary syndrome	0.000269	0.00413	CcSEcCtD
Irbesartan—CYP2D6—female gonad—polycystic ovary syndrome	0.000266	0.00633	CbGeAlD
Irbesartan—Nausea—Metformin—polycystic ovary syndrome	0.000255	0.00391	CcSEcCtD
Irbesartan—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000252	0.00598	CbGeAlD
Irbesartan—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000248	0.00589	CbGeAlD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	1.37e-05	0.000143	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BCL2—polycystic ovary syndrome	1.36e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.36e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	1.35e-05	0.000141	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	1.35e-05	0.000141	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNAS—polycystic ovary syndrome	1.35e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	1.34e-05	0.00014	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL18—polycystic ovary syndrome	1.34e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	1.34e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	1.34e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	1.34e-05	0.00014	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.33e-05	0.000139	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—polycystic ovary syndrome	1.32e-05	0.000138	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	1.31e-05	0.000137	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRG1—polycystic ovary syndrome	1.31e-05	0.000137	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.31e-05	0.000137	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	1.31e-05	0.000136	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.31e-05	0.000136	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SULT2A1—polycystic ovary syndrome	1.3e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.29e-05	0.000134	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.29e-05	0.000134	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—NCOR1—polycystic ovary syndrome	1.28e-05	0.000134	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PGR—polycystic ovary syndrome	1.27e-05	0.000133	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.27e-05	0.000132	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—RRM2—polycystic ovary syndrome	1.26e-05	0.000132	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	1.25e-05	0.00013	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IRS2—polycystic ovary syndrome	1.24e-05	0.000129	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.23e-05	0.000129	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	1.23e-05	0.000128	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	1.22e-05	0.000127	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—YAP1—polycystic ovary syndrome	1.22e-05	0.000127	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP1A1—polycystic ovary syndrome	1.22e-05	0.000127	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.22e-05	0.000127	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—LEP—polycystic ovary syndrome	1.21e-05	0.000127	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GHRL—polycystic ovary syndrome	1.18e-05	0.000123	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PLAT—polycystic ovary syndrome	1.18e-05	0.000123	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NAMPT—polycystic ovary syndrome	1.17e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.16e-05	0.000121	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.16e-05	0.000121	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.16e-05	0.000121	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP11A1—polycystic ovary syndrome	1.15e-05	0.00012	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.15e-05	0.00012	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	1.14e-05	0.000119	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	1.14e-05	0.000119	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.14e-05	0.000119	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—MTHFR—polycystic ovary syndrome	1.13e-05	0.000118	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	1.13e-05	0.000118	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ATF1—polycystic ovary syndrome	1.13e-05	0.000118	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—polycystic ovary syndrome	1.12e-05	0.000117	CbGpPWpGaD
Irbesartan—JUN—Immune System—IRS2—polycystic ovary syndrome	1.12e-05	0.000117	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	1.12e-05	0.000117	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	1.12e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	1.12e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	1.11e-05	0.000116	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.1e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.1e-05	0.000115	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKR1C3—polycystic ovary syndrome	1.09e-05	0.000114	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IRS1—polycystic ovary syndrome	1.08e-05	0.000113	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.08e-05	0.000113	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP17A1—polycystic ovary syndrome	1.07e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	1.07e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	1.06e-05	0.000111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	1.06e-05	0.000111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.05e-05	0.000109	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—POMC—polycystic ovary syndrome	1.04e-05	0.000109	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NGFR—polycystic ovary syndrome	1.04e-05	0.000109	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	1.04e-05	0.000108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—INS—polycystic ovary syndrome	1.04e-05	0.000108	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	1.03e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PRL—polycystic ovary syndrome	1.03e-05	0.000108	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	1.02e-05	0.000107	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	1.01e-05	0.000106	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1—polycystic ovary syndrome	1e-05	0.000105	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1e-05	0.000105	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT2—polycystic ovary syndrome	1e-05	0.000105	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	9.93e-06	0.000104	CbGpPWpGaD
Irbesartan—JUN—Immune System—IRS1—polycystic ovary syndrome	9.82e-06	0.000102	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.79e-06	0.000102	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IRS2—polycystic ovary syndrome	9.73e-06	0.000102	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	9.66e-06	0.000101	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	9.58e-06	0.0001	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.52e-06	9.94e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—LEP—polycystic ovary syndrome	9.52e-06	9.94e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	9.44e-06	9.85e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TH—polycystic ovary syndrome	9.28e-06	9.69e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—polycystic ovary syndrome	9.19e-06	9.59e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	9.14e-06	9.54e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	9.12e-06	9.51e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT2—polycystic ovary syndrome	9.09e-06	9.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	9.08e-06	9.48e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNAS—polycystic ovary syndrome	9.08e-06	9.47e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—POMC—polycystic ovary syndrome	9.06e-06	9.45e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	9.04e-06	9.43e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC2A4—polycystic ovary syndrome	9.03e-06	9.42e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—INS—polycystic ovary syndrome	9.01e-06	9.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	8.82e-06	9.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	8.82e-06	9.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	8.7e-06	9.08e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	8.66e-06	9.04e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.65e-06	9.02e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	8.62e-06	9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	8.56e-06	8.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	8.52e-06	8.89e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IRS1—polycystic ovary syndrome	8.5e-06	8.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP19A1—polycystic ovary syndrome	8.49e-06	8.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRG1—polycystic ovary syndrome	8.49e-06	8.86e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	8.42e-06	8.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—POMC—polycystic ovary syndrome	8.18e-06	8.54e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	8.15e-06	8.5e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—INS—polycystic ovary syndrome	8.14e-06	8.49e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	8.08e-06	8.43e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2—polycystic ovary syndrome	7.94e-06	8.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	7.93e-06	8.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1—polycystic ovary syndrome	7.87e-06	8.21e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT2—polycystic ovary syndrome	7.86e-06	8.21e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	7.86e-06	8.2e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	7.86e-06	8.2e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	7.75e-06	8.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	7.72e-06	8.06e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	7.68e-06	8.02e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—polycystic ovary syndrome	7.67e-06	8e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNAS—polycystic ovary syndrome	7.58e-06	7.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	7.55e-06	7.88e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	7.51e-06	7.83e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	7.5e-06	7.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.47e-06	7.8e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	7.45e-06	7.78e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	7.44e-06	7.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	7.4e-06	7.72e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	7.39e-06	7.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	7.37e-06	7.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	7.28e-06	7.6e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IRS2—polycystic ovary syndrome	7.27e-06	7.59e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NCOR1—polycystic ovary syndrome	7.22e-06	7.53e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—LEP—polycystic ovary syndrome	7.11e-06	7.42e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—polycystic ovary syndrome	7.05e-06	7.36e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	7.04e-06	7.35e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.01e-06	7.31e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	6.93e-06	7.23e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	6.91e-06	7.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	6.9e-06	7.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	6.85e-06	7.15e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A1—polycystic ovary syndrome	6.84e-06	7.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	6.72e-06	7.01e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	6.69e-06	6.98e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	6.69e-06	6.98e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	6.63e-06	6.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	6.57e-06	6.85e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.55e-06	6.84e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	6.45e-06	6.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	6.39e-06	6.67e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTHFR—polycystic ovary syndrome	6.38e-06	6.66e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	6.36e-06	6.64e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IRS1—polycystic ovary syndrome	6.35e-06	6.62e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6.2e-06	6.47e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	6.14e-06	6.41e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	6.12e-06	6.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—POMC—polycystic ovary syndrome	6.11e-06	6.38e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.11e-06	6.37e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—INS—polycystic ovary syndrome	6.08e-06	6.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	6.07e-06	6.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.02e-06	6.29e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—polycystic ovary syndrome	6.02e-06	6.28e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TH—polycystic ovary syndrome	6e-06	6.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	5.96e-06	6.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—polycystic ovary syndrome	5.88e-06	6.14e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT2—polycystic ovary syndrome	5.87e-06	6.13e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	5.85e-06	6.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	5.83e-06	6.09e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.78e-06	6.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	5.73e-06	5.98e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.69e-06	5.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.69e-06	5.93e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	5.67e-06	5.92e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	5.64e-06	5.89e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.58e-06	5.83e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	5.48e-06	5.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	5.46e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	5.25e-06	5.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.22e-06	5.45e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.18e-06	5.41e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	5.18e-06	5.41e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—polycystic ovary syndrome	5.17e-06	5.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.15e-06	5.37e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.14e-06	5.36e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POMC—polycystic ovary syndrome	5.1e-06	5.32e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—INS—polycystic ovary syndrome	5.07e-06	5.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.07e-06	5.29e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.92e-06	5.14e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.91e-06	5.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	4.9e-06	5.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	4.9e-06	5.11e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TH—polycystic ovary syndrome	4.88e-06	5.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	4.82e-06	5.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.79e-06	5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	4.75e-06	4.95e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	4.66e-06	4.87e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—polycystic ovary syndrome	4.53e-06	4.73e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.52e-06	4.71e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.5e-06	4.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	4.46e-06	4.66e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	4.42e-06	4.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.37e-06	4.57e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.22e-06	4.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TH—polycystic ovary syndrome	4.17e-06	4.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	4.12e-06	4.3e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—polycystic ovary syndrome	4.11e-06	4.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	4.06e-06	4.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.05e-06	4.23e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	4.02e-06	4.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4e-06	4.18e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	3.98e-06	4.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.84e-06	4.01e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.83e-06	3.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	3.81e-06	3.98e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	3.8e-06	3.96e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.78e-06	3.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.72e-06	3.88e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.63e-06	3.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	3.6e-06	3.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—polycystic ovary syndrome	3.55e-06	3.71e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	3.4e-06	3.55e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.38e-06	3.53e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	3.35e-06	3.5e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	3.34e-06	3.49e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	3.3e-06	3.44e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—INS—polycystic ovary syndrome	3.28e-06	3.42e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	3.24e-06	3.38e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.22e-06	3.36e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.13e-06	3.27e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	3.07e-06	3.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.94e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	2.87e-06	2.99e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.74e-06	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	2.72e-06	2.84e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.71e-06	2.82e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.69e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	2.68e-06	2.8e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—INS—polycystic ovary syndrome	2.67e-06	2.78e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—polycystic ovary syndrome	2.66e-06	2.77e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.63e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.5e-06	2.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.37e-06	2.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.32e-06	2.43e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.29e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.28e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.21e-06	2.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.79e-06	1.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.77e-06	1.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.76e-06	1.84e-05	CbGpPWpGaD
